Invacare (NYSE:IVC) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

Separately, Zacks Investment Research raised Invacare from a “sell” rating to a “hold” rating in a report on Wednesday, January 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. Invacare currently has a consensus rating of “Hold” and a consensus target price of $21.50.

NYSE:IVC traded up $0.35 on Wednesday, reaching $5.33. 1,762,600 shares of the company’s stock traded hands, compared to its average volume of 709,573. The company has a quick ratio of 1.34, a current ratio of 2.05 and a debt-to-equity ratio of 0.68. The stock has a market cap of $160.02 million, a PE ratio of -2.76 and a beta of 1.95. Invacare has a 12 month low of $3.05 and a 12 month high of $20.00.

Invacare (NYSE:IVC) last posted its quarterly earnings results on Monday, November 5th. The health services provider reported ($0.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.10). The business had revenue of $244.60 million for the quarter, compared to the consensus estimate of $250.59 million. Invacare had a negative net margin of 6.17% and a negative return on equity of 12.98%. Invacare’s revenue was down 2.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.41) earnings per share. Sell-side analysts anticipate that Invacare will post -1.55 earnings per share for the current fiscal year.

In other news, Director Clifford D. Nastas bought 9,000 shares of Invacare stock in a transaction dated Monday, November 19th. The shares were purchased at an average cost of $5.42 per share, with a total value of $48,780.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Matthew E. Monaghan bought 13,750 shares of Invacare stock in a transaction dated Thursday, November 8th. The stock was purchased at an average cost of $7.26 per share, for a total transaction of $99,825.00. Following the completion of the acquisition, the chairman now directly owns 243,897 shares of the company’s stock, valued at approximately $1,770,692.22. The disclosure for this purchase can be found here. Insiders bought 29,250 shares of company stock worth $184,485 over the last ninety days. Insiders own 2.10% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Trexquant Investment LP bought a new stake in shares of Invacare in the third quarter worth about $148,000. AQR Capital Management LLC bought a new stake in shares of Invacare in the third quarter worth about $177,000. SG Americas Securities LLC bought a new stake in shares of Invacare in the second quarter worth about $234,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Invacare in the third quarter worth about $187,000. Finally, Stevens Capital Management LP bought a new stake in shares of Invacare in the third quarter worth about $229,000.

Invacare Company Profile

Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide. The company operates through four segments: North America/Home Medical Equipment, Institutional Products Group, Europe, and the Asia/Pacific.

Further Reading: The mechanics of the bid-ask spread in trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Invacare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invacare and related companies with MarketBeat.com's FREE daily email newsletter.